Analyst Conference Summaries |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
R Pharmaceuticals
|
2023 | |||
Passage Bio Q3 2023 press release |
Passage Bio Q4 2023 press release |
||
Nov. 13, 2023 | Mar. 4, 2024 |
Passage Bio (PASG) is a clinical-stage biotechnology company specializing in therapies for the central nervous system.
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BLUE |
BMY |
CLDX |
CDTX |
DRNA |
EPZM |
GILD |
GLYC |
ILMN |
IMGN |
INCY |
INKT |
INO |
IONS |
MCHP |
MRNA |
PLX |
RETA |
REGN |
RNA |
SAGE |
SANA |
SYRS |
VBLT |
VSTM |
VRTX |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers